[8-K] Xilio Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Xilio Therapeutics (XLO) filed an 8-K stating it announced financial results for the quarter ended September 30, 2025, along with other business highlights. The full details are in a press release furnished as Exhibit 99.1 and incorporated by reference.

The company specifies the information is furnished, not filed, and therefore not subject to liability under Section 18 of the Exchange Act, except as expressly incorporated by reference.

false000184023300018402332025-11-122025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 13, 2025

Xilio Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		001-40925		85-1623397
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

828 Winter Street, Suite 300 Waltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (857) 524-2466

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		XLO		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2025, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit relating to Item 2.02 of this Current Report on Form 8-K shall be deemed to be furnished and not filed.

Exhibit No.		Description
99.1		Press release issued by Xilio Therapeutics, Inc. on November 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	XILIO THERAPEUTICS, INC.
Date: November 13, 2025	By:	/s/ Caroline Hensley
		Caroline Hensley
		Chief Legal Officer

FAQ

What did XLO announce in this 8-K?

It announced financial results for the quarter ended September 30, 2025 and other business highlights, with details in Exhibit 99.1.

Which period does the announcement cover for XLO?

It covers the quarter ended September 30, 2025.

Is the information furnished or filed in this 8-K for XLO?

The information is furnished, not filed, and is not subject to Section 18 liability except as expressly incorporated by reference.

Where can I find the detailed results for XLO?

The detailed results are in the press release furnished as Exhibit 99.1.

What exhibits are included with XLO’s 8-K?

Exhibit 99.1 (press release) and 104 (Cover Page Interactive Data File).

What is the event date mentioned in the 8-K for XLO?

November 13, 2025.